Skip to main content
. 2013 Sep 2;5:437–445. doi: 10.2147/CEOR.S47486

Table 2.

Model clinical efficacy estimates

Parameter Estimate (per 12-week cycle)a Reference
Mortality
 All-cause Age, gender-specific 3
 HIVb 0.9% 4
 AIDSb 3.5% 4
 Acute kidney injury 26.6% 5
 Chronic kidney disease with dialysisc 1.9% 6
Probability of AIDS, given nonsuppressive regimens 1.8% 10
CD4 <50 cells/mm3 (%, among patients with AIDS)d 55.2% 11
Proportion achieving virologic response, mean (range per 12-week cycle)
 First-line
  Atripla® 0.81 (0.28–0.72) 20,21
  Stribild™ 0.85 (0.76–0.89) 20,21
 Second-line 0.49 (0.41–0.57) 22,23
 Third-line 0.51 (0.49–0.57) 10,24,25
Change in CD4 count, mean (range per 12-week cycle)
 First-line
  Atripla 263 (120–367) 2,7,8,9,21
  Stribild 263 (140–426) 2,7,8,9,21
 Second-line 105 (94–109) 7,8,9,26,27
 Third-line 129 (79–147) 7,8,9,10,24,25

Notes:

a

Values are rounded;

b

excess mortality in addition to all-cause;

c

average annual mortality by race weighted using Stribild population distribution;

d

CD4 count ≤200 cells/mm3 among all patients with AIDS.

Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus.